Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm Study to Evaluate Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis

NCT07161258 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07161258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07161258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm Study to Evaluate Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Recruiting
Start date
October 6, 2025
Completion date
February 13, 2029
Enrollment
12 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis